CD109's involvement in cancers such as lung adenocarcinoma, glioblastomas, hepatocellular carcinomas, breast cancer, leukemia, and squamous cell carcinomas highlights its significant impact on immune responses and oncogenic process. Here, CD109 is linked to squamous cell carcinoma.